Stubbe, B.E.; Henriksen, S.D.; Madsen, P.H.; Larsen, A.C.; Krarup, H.B.; Pedersen, I.S.; Johansen, M.N.; Thorlacius-Ussing, O.
Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma. Cancers 2021, 13, 5717.
https://doi.org/10.3390/cancers13225717
AMA Style
Stubbe BE, Henriksen SD, Madsen PH, Larsen AC, Krarup HB, Pedersen IS, Johansen MN, Thorlacius-Ussing O.
Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma. Cancers. 2021; 13(22):5717.
https://doi.org/10.3390/cancers13225717
Chicago/Turabian Style
Stubbe, Benjamin Emil, Stine Dam Henriksen, Poul Henning Madsen, Anders Christian Larsen, Henrik Bygum Krarup, Inge Søkilde Pedersen, Martin Nygård Johansen, and Ole Thorlacius-Ussing.
2021. "Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma" Cancers 13, no. 22: 5717.
https://doi.org/10.3390/cancers13225717
APA Style
Stubbe, B. E., Henriksen, S. D., Madsen, P. H., Larsen, A. C., Krarup, H. B., Pedersen, I. S., Johansen, M. N., & Thorlacius-Ussing, O.
(2021). Validation of SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival and Gemcitabine Effectiveness in Patients with Stage IV Pancreatic Adenocarcinoma. Cancers, 13(22), 5717.
https://doi.org/10.3390/cancers13225717